Review article: Esomeprazole, 40 mg once daily, compared with lansoprazole, 30 mg once daily, in healing and symptom resolution of erosive oesophagitis

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 17, Issue 1, 2003, Pages 21-23

  Vakil, N ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; ESOPHAGOSCOPY; HEALING; HEARTBURN; HUMAN; LIFE TABLE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0037330232     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.17.s1.6.x     Document Type: Conference Paper

References (5)

1. Castell D, Kahrilas P, Richter J, et al. Esomeprazole 40 mg compared with lansoprazole 30 mg in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-83.
2. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80.
3. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 85-92.
4. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-65.
5. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 1249-58.